Hapten-conjugated mammalian cells and methods of making and using thereof
US6403104B1 · kind B1 · utility
Assignee
Inventor
Key dates
| Filing date | Mar 16, 2000 |
| Grant date | Jun 11, 2002 |
| Priority date | — |
| Expiry date | Mar 16, 2020 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2039/6012
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention is directed to mammalian cells conjugated to a hapten and methods of making and using thereof. Conjugating hapten to mammalian cells is a useful way of preventing cells from growing and may be used in the place of any conventional treatment, for example, irradiation. Thus, the invention relates to mammalian cells in general, for example human cells, which cells are in substantially no growth phase and a method of placing the cells in a substantially no growth phase by conjugating them to a hapten. The invention is further directed to compositions containing hapten-modified tumor cells and extracts and methods of treating cancer by administering a therapeutically effective amount of a composition containing a tumor cell or tumor cell extract to a subject in need of such treatment. The tumor cells and extracts of the invention and compositions thereof are capable of eliciting T lymphocytes that have a property of infiltrating a mammalian tumor, eliciting an inflammatory immune response to a mammalian tumor, eliciting a delayed-type hypersensitivity response to a mammalian tumor and/or stimulating T lymphocytes in vitro. The invention also relates to an effective…
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.